Endothelin‐1 receptor blockade as new possible therapeutic approach in multiple myeloma
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14771
Abstract: New effective treatments are needed to improve outcomes for multiple myeloma (MM) patients. Receptors with restricted expression on plasma cells (PCs) represent attractive new therapeutic targets. The endothelin‐1 (EDN1) axis, consisting of EDN1 acting through… read more here.
Keywords: malignant pcs; receptor blockade; multiple myeloma; endothelin receptor ... See more keywords
Pivotal role of PIM2 kinase in plasmablast generation and plasma cell survival, opening new treatment options in myeloma.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014011
Abstract: The differentiation of B cells into plasmablasts (PBs) and then plasma cells (PCs) is associated with extensive cell reprogramming and new cell functions. By using specific inhibition strategies (including a novel morpholino RNA antisense approach),… read more here.
Keywords: pivotal role; pim2 kinase; pim2; role pim2 ... See more keywords
Myelomatous ascites: Flow cytometric diagnosis and evolution of phenotype
Sign Up to like & getrecommendations! Published in 2020 at "Indian Journal of Pathology and Microbiology"
DOI: 10.4103/ijpm.ijpm_450_18
Abstract: Editor, Myeloma is a clonal plasma cell (PC) disorder characterized by presence of a monoclonal M band in either serum or urine and is identified clinically with the presence of myeloma defining events/ biomarkers of… read more here.
Keywords: malignant pcs; cytometric diagnosis; flow cytometric; diagnosis evolution ... See more keywords